CDMO Skyepharma inked a deal to build what is being touted as the largest microbiome production facility in France for the clinical-stage biotech MaaT Pharma. The fa...

Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics-partnered PD-1 inhibitor Tyvyt in the U.S. Now, we have an idea of what the c...

Virpax Pharmaceuticals has brought its nasal spray for acute and chronic pain through an early test. With the National Institutes of Health (NIH) footing the bill, Vi...

Merck & Co. and Eisai’s Lenvima has posted its share of positive data readouts over the years, but bladder cancer remains a tough nut to crack. In newly released ...

In 2017 and 2020, Zejula snagged broad FDA labels for ovarian cancer patients who responded well to chemotherapy. But in prostate cancer, the PARP inhibitor appears t...

The risk of heart-related issues accompanying the use of JAK inhibitors has brought the entire drug class under scrutiny. Last September, the FDA said it will require...

Since snapping up rare disease biopharma Shire for $62 billion back in 2019, Takeda has been boosting its marketing might on conditions not in the mainstream. As we h...

Oncology is hardly what Bayer is known for. But the German drugmaker has raided GlaxoSmithKline—which is itself reestablishing a cancer foothold—for a new leader in t...

Johnson & Johnson has asked U.S. officials to cut in after an activist investor sought to halt sales of the company’s talc-based baby powder abroad. Separately, t...

As Amgen struggles to find growth from its own drugs, the company got a nice late-2021 revenue bump from its manufacturing partnership with Eli Lilly. Monday afterno...